EXICURE INC (XCUR) Stock News

USA - Nasdaq - NASDAQ:XCUR - US30205M3097 - Common Stock

5.54 USD

+0.16 (+2.97%)

Last: 12/2/2025, 8:16:24 PM

5.59 USD

+0.05 (+0.9%)

After Hours: 12/2/2025, 8:16:24 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

XCUR Latest News, Press Relases and Analysis

All

Press Releases

26 days ago - By: Exicure, Inc.

Exicure, Inc. Reports Third Quarter 2025 Financial Results

a month ago - By: Benzinga - Mentions: PMI PRE GNTA URGN ...

12 Health Care Stocks Moving In Friday's After-Market Session

a month ago - By: Halper Sadeh LLC

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

2 months ago - By: Exicure, Inc.

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

3 months ago - By: Benzinga - Mentions: GRI PRPH GLMD COSM ...

12 Health Care Stocks Moving In Thursday's After-Market Session

4 months ago - By: The Motley Fool

Exicure Posts Wider Loss in Fiscal Q2

4 months ago - By: Exicure, Inc.

Exicure, Inc. Reports Second Quarter 2025 Financial Results

4 months ago - By: Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

4 months ago - By: Exicure, Inc.

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

5 months ago - By: Exicure, Inc.

Exicure, Inc. Reports First Quarter 2025 Financial Results

6 months ago - By: Exicure, Inc.

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

7 months ago - By: Exicure, Inc.

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

7 months ago - By: Yahoo Finance - Mentions: TSLA NVDA AAPL

Why Exicure Inc. (XCUR) Soared on Monday

8 months ago - By: Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

8 months ago - By: Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

9 months ago - By: Exicure, Inc.

Exicure, Inc. Reports Full Year 2024 Financial Results

9 months ago - By: Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

10 months ago - By: Stocktwits

Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes

10 months ago - By: Exicure, Inc.

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

a year ago - By: Exicure, Inc.

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

a year ago - By: Exicure, Inc.

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes